The efficacy of tirzepatide is not merely the sum of two metabolic hormones, but the result of a precisely engineered biased dual-agonism that…
Dual-Agonist
The SURMOUNT-MAINTAIN trial results from May 2026 revealed that participants on the maximum tolerated dose of tirzepatide maintained a mean weight…